| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 1b/2b data readout example | Phase 1b/2b | — | Subscribe to access the data. | Biologics | Endocrine System | ||
phase 1b/2b data readout example | Phase 1b/2b | — | Subscribe to access the data. | Biologics | Endocrine System | ||
phase 1b/2b data readout example | Phase 1b/2b | — | Subscribe to access the data. | Biologics | Endocrine System |
Recent Updates
Recently added Catalysts
VYNE Therapeutics Inc.$0.77
+0.01 (+1.38%)
C 45Pipeline Score Fair Value Pharma · Clinical
Market Cap
22.39 M
EPS
-0.53
P/E Ratio
-
Value Trade
97.28 K
SEC Financials
Q1 2026Dilution Risk
25%Revenue
86.00 K
R&D Expenses
817.00 K
Operating CF
-4.08 M
Total Assets
25.87 M
Total Liabilities
1.24 M
Equity
24.64 M
D/E Ratio
12,345
0.24 %
Week
5.8 %
1 Month
12.03 %
3 Month
96.32 %
6 Month
-99.01 %
5 Year
-99.95 %
All Time
Cash Data
Cash Position
24.93 M
Monthly Burn
1.36 M
Runway
16.4 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
1.53 M
52 Week Range
0.28 - 1.96
% held by Insiders
11.4 %
% held by Institutions
39.57 %
Enterprise Value
-2.53 M
Total Shares
33.34 M
Short %
0.35 %
Float Shares
31.60 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for VYNE Therapeutics Inc.
351Total events
9Upcoming
111Tier-1 (high impact)
2018 – 2027Coverage
Upcoming catalysts 2
TBD
T2Quarterly Update
Subscribe to view catalyst details
TBD
T1Acquisition
Subscribe to view catalyst details
Event history 2
TBD
◆Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
●Quarterly UpdateCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2024-09-30 | VYN202 | Phase 1a data readout | Phase 1a | — | – | – | – |
2024-09-30 | VYN202 | Phase 1a data readout | Phase 1a | — | – | – | – |
2024-09-30 | VYN202 | Phase 1a data readout | Phase 1a | — | – | – | – |
Drug Pipeline Intelligence
C45
Pipeline Score $16M
Pipeline ValueFair Value
Valuation Signal11
Drugs Scored0.7x
rNPV / MCap Top 65%
Micro Cap (rank 320 of 912)
Percentile RankVYNE Therapeutics Inc. carries a moderate pipeline score (45/100), with $2.1B risk-adjusted pipeline value, led by Serlopitant in Pruritus (Phase 3), across $58B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Serlopitant Small molecule | Pruritus | Phase 3 | NCT03343639 | 58% | $355M | COMPLETED | 1,501 | - | - | Nov 12, 2018 | - | May 20, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Repibresib | nonsegmental vitiligo | Phase 2b | 2025-07-30 | F VASI50: did not meet; F VASI75: did not meet; F VASI change: Repibresib 3%: -43.6% v. Vehicle: -25.6%; T VASI change: Repibresib 3%: -28.3% v. Vehicle: -16.2%; dropout rates: Repibresib 3% 36.6%, Repibresib 2% 30.2%, Repibresib 1% 26.1%, Vehicle 10.6% Read More | VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo Read More | |
Repibresib | nonsegmental vitiligo | Phase 2b | 2025-07-30 | F VASI50: did not meet; F VASI75: did not meet; F VASI change: Repibresib 3%: -43.6% v. Vehicle: -25.6%; T VASI change: Repibresib 3%: -28.3% v. Vehicle: -16.2%; dropout rates: Repibresib 3% 36.6%, Repibresib 2% 30.2%, Repibresib 1% 26.1%, Vehicle 10.6% Read More | VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo Read More | |
Repibresib | nonsegmental vitiligo | Phase 2b | 2025-07-30 | F VASI50: did not meet; F VASI75: did not meet; F VASI change: Repibresib 3%: -43.6% v. Vehicle: -25.6%; T VASI change: Repibresib 3%: -28.3% v. Vehicle: -16.2%; dropout rates: Repibresib 3% 36.6%, Repibresib 2% 30.2%, Repibresib 1% 26.1%, Vehicle 10.6% Read More | VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in VYNE
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
VYNE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
VYNE▼ -5.1%on this news
VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience
VYNE Therapeutics has announced a special cash dividend of $16.5 million in connection with its proposed merger with Yarrow Bioscience. The dividend, estimated at $0.38 per share, is set to be paid to stockholders and warrant holders of record as of July 22, 2026. The payment is contingent upon the successful closing of the merger, expected around July 24, 2026, pending stockholder approval.
Read more →VYNESEC Filing: Form 4
The article discusses various SEC filings related to VYNE Therapeutics, including statements of changes in beneficial ownership of securities and current reports. It highlights multiple filings over different dates without providing specific details about any particular event or outcome. The content primarily consists of repetitive filing summaries and does not indicate any significant developments.
Read more →VYNESEC Filing: Form ARS
The article discusses various SEC filings related to VYNE Therapeutics, including statements of changes in beneficial ownership and current reports. Multiple filings are noted, indicating ongoing regulatory compliance and corporate governance activities. However, the article does not provide specific details about the implications or outcomes of these filings.
Read more →VYNESEC Filing: Form EFFECT
VYNE Therapeutics has filed multiple SEC documents detailing changes in beneficial ownership of securities. The filings include statements of acquisition by individuals and amendments related to business combinations. The reports cover various dates and types of filings, indicating ongoing regulatory compliance and updates.
Read more →VYNESEC Filing: Form 424B3
The article discusses various SEC filings related to VYNE Therapeutics, including statements of changes in beneficial ownership and current reports. It highlights the ongoing regulatory compliance activities of the company. The filings cover a range of dates and types, indicating the company's active engagement in financial reporting.
Read more →VYNESEC Filing: Form SC 13G
The article discusses various SEC filings related to VYNE Therapeutics, focusing on statements of changes in beneficial ownership of securities. It outlines multiple filings, including quarterly reports and amendments, but does not provide specific details about any significant events or changes. The repetitive nature of the filings suggests ongoing regulatory compliance activities.
Read more →VYNESEC Filing: Form S-4/A
VYNE has filed an SEC Form S-4/A, which includes various statements regarding changes in beneficial ownership of securities. The filing encompasses reports on acquisitions and amendments related to business combinations. It also includes current and quarterly reports, as well as prospectuses and communications pertaining to employee benefit plans.
Read more →VYNEYarrow Bioscience Investor Presentation
Yarrow Bioscience is set to present key investor information, including topline results from the Repibresib Phase 2b trial for vitiligo and data from the VYN202 PsO Phase 1b study. The company has scheduled multiple presentations and events, highlighting its commitment to transparency and investor engagement. The merger with VYNE Therapeutics is also a focal point of recent discussions.
Read more →VYNEBringing life into balance Yarrow Bioscience Overview May 2026 2 Disclaimers The information contained in this presentation has been prepared by Yarrow Bioscience, Inc. and its affiliates ("Yarrow" or t he "Company") and
Yarrow Bioscience, Inc. has presented an overview of its business and operations, emphasizing that the information is subject to change and does not constitute investment advice. The presentation includes forward-looking statements regarding the proposed merger with VYNE Therapeutics and the development of drug candidate YB-101 for Graves' Disease and thyroid eye disease. It cautions that several risks may affect the expected outcomes, including regulatory approvals and market conditions.
Read more →VYNESEC Filing: Form 8-K
The article discusses various SEC filings related to VYNE Therapeutics, including statements of changes in beneficial ownership and current reports. It highlights multiple filings made by the company over a period, indicating ongoing regulatory compliance. The repetitive nature of the filings suggests a routine update process rather than a significant event.
Read more →VYNESEC Filing: Form 10-Q
VYNE has filed its Form 10-Q with the SEC, detailing changes in beneficial ownership of securities. The filing includes various statements regarding acquisitions and amendments related to beneficial ownership. This quarterly report is part of VYNE's ongoing compliance with SEC regulations. The document outlines multiple filings and reports submitted by the company.
Read more →VYNESEC Filing: Form S-4
The article discusses various SEC filings related to VYNE Therapeutics, including statements of changes in beneficial ownership and amendments to registration statements. It lists multiple filings made over several dates, indicating ongoing regulatory compliance and reporting activities. However, no specific details about the implications or outcomes of these filings are provided.
Read more →VYNESEC Filing: Form 10-K
The article discusses various SEC filings related to VYNE Therapeutics, including statements of changes in beneficial ownership and current reports. It highlights multiple filings made over the years, indicating ongoing regulatory compliance. However, there are no specific updates or significant events mentioned in the filings.
Read more →VYNESEC Filing: Form DRS
VYNE has filed various SEC documents, including statements of changes in beneficial ownership and quarterly reports. The filings include amendments and current reports, reflecting ongoing compliance with regulatory requirements. The frequency of these filings indicates active management of corporate governance and transparency in financial reporting.
Read more →VYNESEC Filing: Form 425
The article discusses various SEC filings related to VYNE Therapeutics, including statements of changes in beneficial ownership and current reports. Multiple filings are noted, with dates ranging from 2023 to 2026. The content primarily consists of repetitive mentions of ownership changes and regulatory compliance without specific details on implications or outcomes.
Read more →VYNEVYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement
VYNE Therapeutics and Yarrow Bioscience have announced a merger agreement, with the combined entity expected to operate as Yarrow Bioscience, Inc. The merger is supported by a $200 million financing commitment and aims to advance YB-101, a clinical-stage antibody for Graves' disease and thyroid eye disease. The merger is anticipated to close in Q2 2026, pending shareholder approval.
Read more →VYNESEC Filing: Form SCHEDULE 13G/A
The article discusses multiple SEC filings related to VYNE Therapeutics, including statements of changes in beneficial ownership of securities. It highlights various filing dates and types, such as current reports and quarterly reports. The repetitive nature of the filings indicates ongoing regulatory compliance but lacks specific new developments or changes.
Read more →VYNESEC Filing: Form DEF 14A
The article discusses various SEC filings related to VYNE Therapeutics, including statements of changes in beneficial ownership and current reports. It lists multiple filings made on different dates, indicating ongoing compliance with regulatory requirements. The content primarily consists of repetitive mentions of filings without specific details on outcomes or implications.
Read more →VYNEVYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update
VYNE Therapeutics reported its financial results for Q3 2025, highlighting a strategic review to maximize shareholder value. The company initiated a toxicology study for VYN202, aiming to resolve a clinical hold. Despite a net loss of $7.3 million, VYNE's cash reserves are projected to sustain operations into 2027.
Read more →VYNEVYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update
VYNE Therapeutics reported its financial results for Q2 2025, highlighting promising data for its oral BD2-selective BET inhibitor, VYN202, in a Phase 1b trial for plaque psoriasis. The company has extended its cash runway into 2027 through cost reductions. However, a clinical hold on VYN202 due to safety concerns and disappointing results from the repibresib gel trial present challenges.
Read more →VYNEVYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update Implemented cost reductions extend cash runway into first half of 2027 BRIDGEWATER, N.J.
VYNE Therapeutics reported its financial results for the second quarter of 2025, highlighting a net loss of $5.8 million and reduced revenue. However, the company noted promising efficacy signals from its oral BD2-selective BET inhibitor, VYN202, in clinical trials. Furthermore, VYNE has implemented cost reduction measures that will extend its cash runway into the first half of 2027, allowing continued evaluation of its pipeline and potential partnerships.
Read more →VYNE▼ -72.4%on this news
VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo
VYNE Therapeutics announced that its Phase 2b trial of Repibresib gel for nonsegmental vitiligo failed to meet its primary endpoint of F-VASI50 improvement. Although nominally significant effects were noted in secondary endpoints, the trial's outcomes were influenced by a high vehicle effect and dropout rates. The company plans to terminate the trial's extension phase and seek a development partner for Repibresib.
Read more →VYNE▼ -72.4%on this newsshared move
Repibresib Phase 2b Vitiligo Topline Results
VYNE Therapeutics has announced the topline results from the Phase 2b trial of Repibresib for vitiligo. The results are expected to be presented on July 30, 2025, alongside additional analyses. The company continues to engage with investors through various presentations and calls, highlighting its commitment to transparency and growth.
Read more →VYNEVYNE Investor Relations Presentation
VYNE Therapeutics has detailed its upcoming and past investor presentations, highlighting key events such as the Repibresib Phase 2b vitiligo results and VYN202 data presentations. The company is also preparing for a merger conference call with Yarrow Bioscience. These activities reflect VYNE's commitment to transparency and investor engagement.
Read more →VYNE▼ -14.7%on this news
VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202
VYNE Therapeutics announced an update on its oral BET inhibitor VYN202, following the lifting of a clinical hold by the FDA for female patients on specific doses. The hold was initially placed due to testicular toxicity observed in dogs. While the company will not enroll more patients in the Phase 1b psoriasis study, it aims to progress VYN202 for serious immune-mediated diseases and extend its cash runway into late 2026.
Read more →VYNE▼ -14.7%on this newsshared move
VYN202 PsO Phase 1b Data Presentation
VYNE Therapeutics is set to present data from the Phase 1b trial of VYN202 for psoriasis on July 2, 2025. This presentation is part of a series of investor events highlighting the company's ongoing research and development efforts. The data presentation is anticipated to provide insights into the drug's efficacy and safety profile.
Read more →VYNE▼ -5.1%on this news
VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update
VYNE Therapeutics reported its financial results for Q1 2025, highlighting progress in its Phase 2b trial for repibresib gel targeting vitiligo, with top-line results expected mid-2025. The company has a cash runway extending into the second half of 2026, but faces a clinical hold on its Phase 1b trial for VYN202 due to safety concerns. Overall, VYNE continues to focus on developing therapies for chronic inflammatory conditions.
Read more →VYNE▼ -5.1%on this newsshared move
VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update Repibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025 Expected cash runway into 2H 2026 BRIDGEWATER, N
VYNE Therapeutics has released its first-quarter financial results for 2025, alongside a business update highlighting progress in its Phase 2b trial for repibresib gel targeting vitiligo. The company expects top-line trial results by mid-2025 and has reported sufficient cash to support operations into the second half of 2026. However, the company faces challenges as the FDA has placed a clinical hold on its Phase 1b psoriasis trial for VYN202 due to toxicology concerns in animal studies. The financial report noted a net loss increase compared to the previous year.
Read more →VYNE▼ -23.9%on this news
VYNE Therapeutics Provides Update on VYN202 Program
VYNE Therapeutics announced a clinical hold on its Phase 1b study for VYN202 due to observed testicular toxicity in dogs. This hold halts all patient-related activities while the company works with the FDA to resolve the issue. No serious adverse events have been reported in enrolled subjects. The hold does not affect the ongoing Phase 2b trial of repibresib gel.
Read more →VYNE▼ -5.1%on this news
VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
VYNE Therapeutics Inc. will participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 27, 2025. The company aims to showcase its differentiated therapies targeting chronic inflammatory and immune-mediated conditions. A webcast replay will be available for 90 days post-event, highlighting VYNE's commitment to transparency and investor engagement.
Read more →VYNE▼ -5.1%on this newsshared move
VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
VYNE Therapeutics Inc. will participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 27, 2025. The company, which specializes in therapies for chronic inflammatory and immune-mediated conditions, aims to showcase its unique BET inhibitors during the event. A webcast replay will be available for 90 days post-conference.
Read more →VYNEVYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update
VYNE Therapeutics reported its financial results for the fourth quarter and year-end 2024, highlighting significant progress in its clinical trials. The company expects to announce top-line results for repibresib gel in mid-2025 and has initiated a Phase 1b trial for VYN202 with results anticipated by the end of 2025. VYNE's cash runway is projected to extend into the second half of 2026.
Read more →VYNEVYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update Repibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025 VYN202 Phase 1b psoriasis trial in
VYNE Therapeutics has reported its financial results for the fourth quarter and year-end 2024, detailing a significant net loss of $39.8 million. The company is moving forward with key developments, including the Phase 2b trial of repibresib gel for vitiligo, with top-line results expected in mid-2025, and the initiation of the Phase 1b trial for VYN202 in psoriasis, which should yield results by the end of 2025. VYNE indicates it has a cash position that should sustain its operations through the second half of 2026, but the increase in research and development spending reflects ongoing investment in clinical trials.
Read more →VYNE▲ +7.1%on this news
VYNE Therapeutics to Participate in March Investor Conferences
VYNE Therapeutics Inc. has announced its participation in two investor conferences scheduled for March. The company, which specializes in therapies for chronic inflammatory and immune-mediated conditions, aims to engage with investors and share insights about its innovative BET inhibitors. A webcast replay will be available for 90 days post-event.
Read more →VYNEVYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis
VYNE Therapeutics has commenced a Phase 1b trial for VYN202, an oral BET inhibitor aimed at treating moderate-to-severe plaque psoriasis. The trial will assess the safety and pharmacokinetics of VYN202 over 12 weeks, with results expected by the end of 2025. This trial follows promising data from earlier studies indicating a favorable safety profile.
Read more →VYNE▼ -12%on this news· ran to -25% by day 3
Corporate Presentation January 2025 Forward Looking Statements and Important Notes This presentation by VYNE Therapeutics Inc. (“VYNE”) includes forward-looking statements within the meaning of the Private
VYNE Therapeutics recently presented data on VYN202, a novel oral treatment targeting immune-mediated disorders. The Phase 1a results indicate a favorable safety profile with no drug-related adverse events reported. The drug demonstrated dose-dependent pharmacokinetics and significant inhibitory effects on inflammatory biomarkers. Upcoming top-line results from a Phase 1b trial in moderate-to-severe plaque psoriasis are expected by the end of 2025.
Read more →VYNE▲ +15.6%on this news
VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo
VYNE Therapeutics has announced the completion of patient enrollment in its Phase 2b trial for VYN201, now known as repibresib, aimed at treating nonsegmental vitiligo. The trial, which involves multiple dose cohorts, will evaluate the gel's efficacy and safety over a 24-week period, with top-line data expected in mid-2025. Vitiligo, a chronic skin condition, currently has limited treatment options, highlighting the potential impact of VYN201 on patient care. The advancement in clinical trials marks a significant milestone for VYNE as it continues to develop therapies for unmet medical needs.
Read more →VYNEVYN202 P1a SAD/MAD Data
VYNE has provided an overview of its corporate structure and pipeline, including details about its InhiBET™ BET Inhibitor Platform and specific products like VYN201 and VYN202. The article primarily focuses on corporate governance, investor relations, and the company's mission. However, it lacks specific updates or data regarding the clinical progress of VYN202.
Read more →VYNEVYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor
VYNE Therapeutics announced positive results from the Phase 1a MAD trial of VYN202, a novel BD2-selective BET inhibitor. The trial demonstrated a favorable safety profile with no serious adverse events and robust pharmacodynamic activity. VYN202 showed potential for once-daily oral administration, targeting immune-mediated disorders effectively. The company is optimistic about further clinical development based on these results.
Read more →VYNEVYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor Promising results support VYN202's potential as a novel, once-daily oral treatment for a broad range of immu
VYNE Therapeutics announced positive top-line results from the Phase 1a multiple ascending dose (MAD) trial of VYN202, a novel BD2-selective BET inhibitor. The trial data showed favorable safety, pharmacokinetics, and pharmacodynamics in healthy volunteers, supporting further development of VYN202 for immune-mediated diseases. CEO David Domzalski emphasized that the results validate the drug's design and its potential to offer a convenient oral treatment option. The company plans to finalize its clinical trial strategy for VYN202 in patients for longer durations.
Read more →VYNESEC Filing: Form S-8
VYNE has filed multiple SEC documents, including statements of changes in beneficial ownership and current reports. These filings include various amendments and prospectuses related to securities offered to employees and business combinations. The filings reflect ongoing compliance with regulatory requirements.
Read more →VYNESEC Filing: Form SC 13G/A
The article discusses various SEC filings related to VYNE Therapeutics, including statements of changes in beneficial ownership and other financial reports. It lists multiple filings with specific dates and types, indicating ongoing regulatory compliance. However, no significant news or changes in ownership are highlighted.
Read more →VYNEVYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
VYNE Therapeutics reported its Q3 2024 financial results, highlighting significant progress in its clinical trials. The Phase 2b trial for VYN201 in vitiligo exceeded enrollment targets, while positive data from the Phase 1a trial of VYN202 was announced. The company maintains a strong cash position, expected to support operations through 2025.
Read more →VYNEVYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update VYN201 Phase 2b vitiligo trial exceeds enrollment target Expected to be fully enrolled in December 2024 with top-line results on
VYNE Therapeutics reported its third-quarter 2024 financial results, indicating significant progress in its clinical trials. The Phase 2b trial for VYN201 has exceeded its enrollment target and is expected to be fully enrolled by December 2024, with top-line results anticipated in mid-2025. Additionally, the recent Phase 1a SAD data for VYN202 were positive, and results from the MAD portion are expected by the end of Q4 2024. However, the company reported a net loss of $12.2 million for the quarter.
Read more →VYNEVYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor
VYNE Therapeutics announced positive results from the Phase 1a SAD trial of VYN202, a BD2-selective BET inhibitor. The trial showed that VYN202 was well tolerated with no adverse events and demonstrated dose-dependent pharmacokinetics and pharmacodynamic activity on inflammatory biomarkers. The MAD portion of the trial has begun, with results expected in Q4 2024.
Read more →VYNEVYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor VYN202 was generally well tolerated with no drug-related adverse events Pharmacokinetic results demonstrated dose-dep
VYNE Therapeutics announced positive results from the Phase 1a SAD trial of VYN202, a BD2-selective BET inhibitor. The trial demonstrated that VYN202 was generally well tolerated with no drug-related adverse events reported. Additionally, the pharmacokinetic results showed a dose-dependent increase in drug concentrations, suggesting effective dose management. The next phase of the trial, encompassing multiple ascending doses, has been initiated to further evaluate the drug's safety and pharmacodynamics, with results expected by Q4 2024.
Read more →VYNEVYNE Therapeutics to Participate in September Investor Conferences
VYNE Therapeutics Inc. has announced its participation in two upcoming investor conferences in September 2024. The first event is the H.C. Wainwright 26th Annual Global Investment Conference in New York, and the second is the Stifel 2024 Virtual Immunology and Inflammation Summit. During these events, management will engage in one-on-one meetings and present insights into their clinical-stage biopharmaceutical programs, particularly their unique BET inhibitors. Interested investors can access a webcast replay on the company's website following the events.
Read more →VYNEVYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
VYNE Therapeutics reported its financial results for Q2 2024, highlighting the initiation of a Phase 2b trial for VYN201 and ongoing Phase 1a trial for VYN202. The company is on track to release top-line data for both trials in the upcoming quarters. Despite a net loss of $9.4 million, VYNE's financial position is expected to support its clinical programs through 2025.
Read more →VYNEVYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Initiated Phase 2b trial of VYN201 in nonsegmental vitiligo, with top-line results expected in mid-2025 Phase 1a SAD MAD trial
VYNE Therapeutics has reported its financial results for the second quarter of 2024, highlighting the initiation of a Phase 2b clinical trial for its product VYN201 in nonsegmental vitiligo. The company also updated progress on its Phase 1a trial for VYN202, with data expected to be reported in the third and fourth quarters of 2024. VYNE's financial status appears solid, anticipating sufficient funds to support its clinical milestones through the end of 2025. However, the company recorded a net loss of $9.4 million during the quarter, alongside low revenue figures.
Read more →VYNEVYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor
VYNE Therapeutics has announced the granting of a significant composition of matter patent for its novel BD2-selective BET inhibitor, VYN202, by the UK's Intellectual Property Office. The patent extends protection for the compound until June 2042, strengthening VYNE's intellectual property portfolio as it seeks to enhance its BET inhibitor pipeline. VYN202 is positioned to potentially offer a convenient non-biologic treatment option for various immuno-inflammatory conditions, aiming for class-leading potency and selectivity.
Read more →VYNEVYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development
VYNE Therapeutics has appointed Dr. Subhashis Banerjee as Senior Vice President of Clinical Development, effective July 8, 2024. Dr. Banerjee, an experienced immunologist and rheumatologist, previously held significant roles at Bristol Myers Squibb and Eli Lilly. His appointment is considered timely as VYNE embarks on advancing its clinical programs, particularly in the development of BET inhibitors for immuno-inflammatory conditions. The decision underscores the company's commitment to enhancing its research and development capabilities in a competitive biopharmaceutical landscape.
Read more →VYNE▼ -7.5%on this news
VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum
VYNE Therapeutics Inc. has announced that its management team will participate in one-on-one meetings at the upcoming Leerink Partners Therapeutics Forum, scheduled for July 9, 2024. This event focuses on Immunology, Inflammation, and Metabolic Diseases and represents a significant opportunity for the company to showcase its innovative therapies. VYNE is actively developing differentiated treatments for immuno-inflammatory conditions, including products within its InhiBET™ platform.
Read more →VYNEVYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202
VYNE Therapeutics has initiated a Phase 1a trial for its novel BD2-selective BET inhibitor, VYN202, by dosing the first healthy participants. This trial aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of VYN202, with top-line results anticipated in the second half of 2024. VYN202 is positioned as a promising treatment for immuno-inflammatory diseases, informed by positive preclinical outcomes showing reductions in biomarkers associated with inflammation.
Read more →VYNEVYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201
VYNE Therapeutics has commenced dosing the first subject in its Phase 2b trial for VYN201, a topical gel treatment for nonsegmental vitiligo. This trial aims to evaluate the safety and efficacy of VYN201 through a 24-week vehicle-controlled treatment, with results expected in mid-2025. With a unique formulation designed for local delivery, VYN201 has previously demonstrated significant clinical responses in earlier trials. Vitiligo, a common depigmenting skin condition, currently has limited treatment options, making this trial particularly relevant.
Read more →VYNEVYNE Reports First Quarter 2024 Financial Results and Provides Business Update
VYNE Therapeutics reported its Q1 2024 financial results, highlighting progress in its clinical trials. The Phase 2b trial for VYN201 is set to begin this quarter, with an expected enrollment of 160 subjects. Additionally, the company received IND clearance for VYN202, anticipating the start of a Phase 1a trial soon. Despite a strong cash position, VYNE reported an increased net loss compared to the previous year.
Read more →VYNEVYNE Reports First Quarter 2024 Financial Results and Provides Business Update Design of Phase 2b trial for VYN201 in nonsegmental vitiligo finalized and on track to begin this quarter Phase 2b trial expected to enroll a
VYNE Therapeutics reported its financial results for the first quarter of 2024 and provided a business update. The company is set to commence a Phase 2b trial for VYN201 in nonsegmental vitiligo, which is expected to enroll about 160 subjects. Additionally, VYNE received IND clearance for VYN202 and anticipates dosing the first healthy volunteers in an upcoming Phase 1a trial. Despite a net loss of $6.2 million, VYNE maintains a strong cash position, sufficient to fund operations through the end of 2025.
Read more →VYNEVYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor
VYNE Therapeutics has received FDA clearance for its IND application for VYN202, an innovative oral BD2-selective BET inhibitor. This advancement allows VYNE to initiate a Phase 1a trial in healthy volunteers, aiming to evaluate the drug's safety and pharmacokinetics. Preclinical studies have shown VYN202's potential in mitigating inflammation-related biomarkers. Future trials are planned to assess the drug's effects on various autoimmune diseases, with results expected by late 2025.
Read more →VYNEVYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting
VYNE Therapeutics announced the selection of two abstracts for oral presentations of its BET inhibitor, VYN201, at the upcoming 2024 Society for Investigative Dermatology Annual Meeting. The presentations will focus on positive preclinical and Phase 1b data supporting VYN201 as a therapy for nonsegmental vitiligo. The Phase 1b trial results indicate significant clinical improvements and good tolerability among participants. This marks a notable advancement in developing treatments for a condition that currently has limited approved therapies.
Read more →VYNE▲ +8.9%on this news· ran to +26% by day 3
VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
VYNE Therapeutics Inc. has announced its participation in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference. The conference will include a fireside chat featuring President and CEO David Domzalski and Chief Scientific Officer Dr. Iain Stuart on March 28, 2024. This event highlights VYNE's focus on developing innovative therapies for immuno-inflammatory conditions and its engagement with the medical community.
Read more →VYNESEC Filing: Form CORRESP
VYNE has filed multiple SEC documents detailing changes in beneficial ownership of securities. The filings include statements of acquisition by individuals and various reports such as quarterly and annual reports. There is a focus on compliance with SEC regulations and updates regarding beneficial ownership.
Read more →VYNESEC Filing: Form UPLOAD
VYNE has filed multiple SEC documents, including statements of changes in beneficial ownership and quarterly reports. The filings cover various aspects of securities registration and ownership acquisition. This activity indicates ongoing compliance with regulatory requirements but lacks significant news or developments.
Read more →VYNESEC Filing: Form S-3
VYNE has filed various SEC documents, including statements of changes in beneficial ownership and quarterly reports. The filings include amendments and current reports, reflecting ongoing compliance with regulatory requirements. The documents detail acquisitions and ownership changes, indicating active management of securities.
Read more →VYNEVYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update
VYNE Therapeutics reported its financial results for Q4 and the year ending December 31, 2023, highlighting a transformative year with clinical proof-of-concept for VYN201 in vitiligo. The company plans to initiate a Phase 2b trial for VYN201 and a Phase 1a trial for VYN202 in Q2 2024. Despite a net loss of $28.5 million, VYNE ended the year with $93.3 million in cash, providing a runway through 2025.
Read more →VYNEVYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update 2023 was a transformative year for VYNE, marked by the achievement of clinical proof-of-concept for VYN201 in vitiligo and a su
VYNE Therapeutics reported its fourth-quarter and year-end financial results for 2023, revealing significant progress in clinical development and funding. The company achieved clinical proof-of-concept for VYN201 in treating vitiligo and plans to start a Phase 2b trial in Q2 2024. VYNE ended the year with $93.3 million, which is expected to sustain operations through the end of 2025. Despite these advancements, the company reported increased net losses compared to the previous year.
Read more →VYNEVYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium
VYNE Therapeutics announced that it will present results from a Phase 1b trial of its BET inhibitor VYN201 targeting vitiligo at the upcoming Global Vitiligo Foundation Annual Scientific Symposium. The presentation will include data indicating positive safety and efficacy outcomes from the trial, supporting the advancement into a Phase 2b trial expected to start in the next quarter. The Phase 1b study involved 29 participants and showed promising clinical improvements, particularly in reducing the severity of vitiligo symptoms.
Read more →VYNEVYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
VYNE Therapeutics Inc. announced that its CEO, David Domzalski, will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference on March 4, 2024. The conference, held in Boston, will provide an opportunity for investors to engage in one-on-one meetings with the management. VYNE is focused on developing innovative therapies targeting immuno-inflammatory conditions, utilizing its proprietary InhiBET™ platform.
Read more →VYNEVYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo
VYNE Therapeutics has announced positive biomarker data from its Phase 1b trial of VYN201, a treatment for vitiligo. The trial reported reductions in inflammatory biomarkers and significant upregulation of melanocyte-related transcription factors, indicating VYN201's potential to target vitiligo effectively. The company plans to initiate a Phase 2b trial in Q2 2024 to further evaluate the treatment's efficacy in patients. This data builds on previously reported clinical results, highlighting VYN201's promising role in vitiligo therapy.
Read more →VYNEVYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors BRIDGEWATER, N.J.
VYNE Therapeutics has appointed Dr. Christine Borowski to its Board of Directors effective January 1, 2024. Her extensive background in immunology and biopharmaceuticals is expected to contribute positively to VYNE's goals of advancing its InhiBET platform and developing novel therapies. Dr. Borowski's previous roles include Vice President at Access Biotechnology and Chief Editor of Nature Medicine, indicating her strong credentials in the field.
Read more →VYNESEC Filing: Form 3
The article discusses various SEC filings related to VYNE Therapeutics, including statements of changes in beneficial ownership and current reports. It highlights the ongoing regulatory documentation process but does not provide specific details on any significant changes or events. The filings appear to be routine and part of the company's compliance with SEC requirements.
Read more →VYNESEC Filing: Form D
VYNE has filed multiple SEC documents detailing changes in beneficial ownership of securities. The filings include statements of acquisition by individuals and amendments to previous filings. This activity is part of the company's ongoing compliance with SEC regulations regarding ownership disclosures.
Read more →VYNEVYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
VYNE Therapeutics reported a successful capital raise of $88.2 million, extending its funding through 2025. The company is advancing its VYN201 program for vitiligo, following positive Phase 1b results, and plans to submit an IND for VYN202 by the end of 2023. Despite a net loss of $6.6 million in Q3 2023, VYNE remains optimistic about its pipeline and financial position.
Read more →VYNESEC Filing: Form SC 13D
The article discusses various SEC filings related to VYNE Therapeutics, including statements of changes in beneficial ownership and current reports. It lists multiple filings made over the years, indicating ongoing regulatory compliance and corporate governance activities. However, no specific events or changes are highlighted in the article.
Read more →VYNEVYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update Transformative capital raise of $88.2 million from leading healthcare investors provides funding for BET inhibitor programs thro
VYNE Therapeutics reported its financial results for Q3 2023, highlighting a successful capital raise of $88.2 million to support its BET inhibitor programs through 2025. The company is progressing with preparatory activities for VYN201 in nonsegmental vitiligo and is on track for an IND submission for VYN202 by the end of 2023. Despite a significant net loss of $6.6 million in Q3, VYNE's management expressed optimism regarding the advancement of its clinical pipeline and financial strategy.
Read more →VYNE▲ +7.7%on this news
VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023
VYNE Therapeutics is set to host a virtual R&D Day on November 9, 2023, to discuss the results of its VYN201 Phase 1b trial and preclinical data for VYN202. The event will feature a presentation by Dr. Amit Pandya, focusing on the treatment landscape for vitiligo. VYNE aims to highlight its clinical development plans for both therapies.
Read more →VYNE▲ +7.7%on this newsshared move
VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023
VYNE Therapeutics Inc. has announced a virtual R&D Day event scheduled for November 9, 2023. The event will highlight key developments including results from the Phase 1b trial of VYN201 and the preclinical data for VYN202. Dr. Amit Pandya, a recognized expert in vitiligo, will present along with VYNE management discussing their clinical development plans. The event will also feature a live Q&A session for attendees.
Read more →VYNEVYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million
VYNE Therapeutics Inc. has announced the closing of its private placement financing, securing $88.2 million through the sale of over 10.6 million shares of common stock and pre-funded warrants. This financing complies with Nasdaq's minimum price requirements and is intended to support VYNE's development of therapies for immuno-inflammatory conditions. The company has committed to filing a registration statement with the SEC for the resale of the issued shares. LifeSci Capital LLC acted as the exclusive placement agent for this transaction.
Read more →VYNE▲ +23.4%on this newsshared move
VYNE Therapeutics Announces Private Placement of $88 Million
VYNE Therapeutics has announced a private placement financing that will provide $88 million to support its clinical development programs for VYN201 and VYN202 through 2025. The financing, led by Access Biotechnology, will help advance VYN201 into a Phase 2b trial and initiate Phase 1 trials for VYN202. The PIPE is expected to close on November 1, 2023.
Read more →VYNE▲ +23.4%on this newsshared move
VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo
VYNE Therapeutics has announced positive preliminary data from its Phase 1b trial of VYN201, a novel BET inhibitor, in patients with nonsegmental vitiligo. The trial demonstrated significant dose-dependent reductions in facial vitiligo area scoring index (F-VASI) scores, particularly in the 1.0% and 2.0% dose cohorts. The drug was well-tolerated, with no serious adverse events reported. VYNE plans to advance VYN201 into a Phase 2b trial in the first half of 2024.
Read more →VYNE▲ +23.4%on this newsshared move
VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202
VYNE Therapeutics reported encouraging preclinical results for its oral BD2-selective BET inhibitor, VYN202, indicating its potential for treating psoriasis and rheumatoid arthritis. Notably, treatment with VYN202 showed significant reductions in inflammatory biomarkers and improvements in clinical symptoms in animal models. The company is set to initiate a Phase 1a clinical trial in early 2024, followed by Phase 1b trials later in the year. VYNE's management has expressed optimism about the compound's therapeutic potential.
Read more →VYNE▲ +23.4%on this newsshared move
VYNE Therapeutics Announces Private Placement of $88 Million Transaction provides $88 million to fund VYNE's clinical development programs for VYN201 and VYN202 through the end of 2025 BRIDGEWATER, N.J.
VYNE Therapeutics has announced a private placement financing that is expected to generate gross proceeds of $88 million. The funds will be used to support VYNE's clinical development programs for VYN201, which has shown positive Phase 1b trial results, and VYN202. The financing was led by Access Biotechnology and will help advance VYNE's InhiBET platform's clinical trials. The transaction is set to close on November 1, 2023, subject to standard conditions.
Read more →VYNEVYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference from September 11-13, 2023. CEO David Domzalski will present and meet with investors during the event. The company's focus is on developing unique therapies for immuno-inflammatory conditions, including its novel bromodomain inhibitors. A replay of the presentation will be available on the VYNE website for 90 days post-conference.
Read more →VYNE▲ +9.3%on this news
VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
VYNE Therapeutics reported its Q2 2023 financial results, highlighting progress in its BET inhibitor programs. The company anticipates preliminary Phase 1b data for VYN201 in non-segmental vitiligo by Q3 2023 and plans to initiate a Phase 1 trial for VYN202 in Q1 2024. Despite a net loss increase, VYNE maintains a positive outlook on its drug development pipeline.
Read more →VYNE▲ +9.3%on this newsshared move
VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update Anticipate announcing preliminary Phase 1b safety and efficacy data for pan-BD BET inhibitor, VYN201, in nonsegmental vitiligo
VYNE Therapeutics has reported its financial results for Q2 2023 and provided a business update, highlighting progress with its drug candidates VYN201 and VYN202. The company anticipates preliminary Phase 1b data for VYN201, targeting non-segmental vitiligo, in Q3 2023. Furthermore, IND-enabling studies for VYN202 are ongoing with an expected lead indication selection in Q4 2023 and a Phase 1 trial initiation projected for Q1 2024. Despite reporting an increased net loss compared to last year, VYNE expresses confidence in its drug developments and financial strategy.
Read more →VYNE▼ -5.6%on this news
VYNE Therapeutics to Attend BIO International Convention
VYNE Therapeutics Inc. has announced its attendance at the BIO International Convention from June 5-8, 2023, in Boston, Massachusetts. The company plans to engage in partnering and investor meetings, focusing on its pipeline of bromodomain & extra-terminal (BET) domain inhibitors. This event represents a significant opportunity for VYNE to showcase its innovative therapies and establish connections with potential investors.
Read more →VYNEVYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update Anticipate topline 16-week data for all three cohorts from the Phase 1b trial for pan-BD BET inhibitor, VYN201, in nonsegmental
VYNE Therapeutics reported its financial results and business updates for Q1 2023, highlighting progress in its clinical pipeline. The company plans to release topline data for its VYN201 trial in nonsegmental vitiligo in Q3 2023, with positive results reported for its safety and pharmacokinetics in earlier trials. Additionally, VYNE has selected a lead candidate for its oral BET inhibitor program, VYN202, expected to enhance its pipeline. Despite growth in clinical capabilities, the company reported a net loss of $5.6 million this quarter, reflecting challenges in revenue generation.
Read more →VYNE▲ +14.8%on this news· ran to +39% by day 3
VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions Preclinical studies sug
VYNE Therapeutics has selected VYN202 as a development candidate, an oral BD2-selective BET inhibitor intended for treating immuno-inflammatory conditions. The compound has exhibited potent anti-inflammatory and anti-fibrotic effects in various preclinical models. The company plans to file an Investigational New Drug application by year-end while continuing to advance its IND-enabling studies. VYNE aims to leverage its InhiBET platform, which includes multiple promising BD2-selective inhibitors, to enhance treatment options for autoimmune diseases.
Read more →VYNE▲ +42.5%on this news
VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis
VYNE Therapeutics announced positive preclinical data for its novel pan-BET inhibitor, VYN201, in treating idiopathic pulmonary fibrosis (IPF). VYN201 showed significant reductions in lung fibrosis and improvements in key lung function metrics in a murine model. The drug's potential as a locally-administered therapy for immuno-inflammatory conditions was highlighted. The data suggest a promising future for VYN201 in clinical applications, especially considering current limited treatment options for IPF.
Read more →VYNE▲ +16.4%on this news
VYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201
VYNE Therapeutics announced encouraging first-in-human data from its Phase 1a trial for the novel BET inhibitor, VYN201. The trial demonstrated that VYN201 had no quantifiable plasma concentrations in participants, indicating minimal systemic exposure and no adverse effects on hematological parameters, including platelet counts. These results position VYN201 favorably compared to traditional systemic therapies for conditions like nonsegmental vitiligo. The company expects to release additional topline results from the Phase 1b trial in mid-2023.
Read more →VYNE▼ -6.6%on this news
VYNE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference
VYNE Therapeutics Inc. announced that its CEO David Domzalski and Chief Scientific Officer Dr. Iain Stuart will participate in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference on March 30, 2023. The event will include a fireside chat and 1-on-1 meetings with investors. VYNE is dedicated to developing innovative therapies targeting immuno-inflammatory conditions.
Read more →VYNEVYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update First vitiligo patients being treated with pan-BD BET inhibitor, VYN201, for up to 16 weeks in Phase 1b clinical trial Anticipate top
VYNE Therapeutics reported its year-end financial results and provided an update on its ongoing clinical trials, particularly focusing on the Phase 1b trial of its BET inhibitor, VYN201, for the treatment of nonsegmental vitiligo. The initial safety data from the Phase 1a trial was positive, allowing the transition to further testing in a larger patient population. The company anticipates topline Phase 1b data in mid-2023, highlighting the potential of VYN201 as a novel treatment in a market with limited options. However, VYNE reported a significant financial loss in 2022 and faces challenges in proving the commercial success of its therapies.
Read more →VYNEVYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule BRIDGEWATER, N.J.
VYNE Therapeutics Inc. announced that it has regained compliance with the Nasdaq minimum bid price rule, receiving a notification letter confirming this status. The company maintained a closing bid price of $1.00 per share or greater for ten consecutive business days. This development reflects positively on VYNE's market position and its ongoing commitment to developing innovative therapies for immuno-inflammatory conditions.
Read more →VYNEVYNE Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference
VYNE Therapeutics Inc. announced its participation in the 43rd Annual Cowen Health Care Conference, scheduled for March 7, 2023. CEO David Domzalski will hold a fireside chat during the event and will be available for individual meetings with investors. This engagement reflects the company's commitment to sharing advancements in its immuno-inflammatory treatment pipeline. A replay of the conference webcast will be accessible on VYNE's website for 90 days post-event.
Read more →VYNEVYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201
VYNE Therapeutics announced positive results from the Phase 1a trial of its investigational BET inhibitor, VYN201, for treating vitiligo. The study, which involved 30 healthy volunteers, demonstrated that VYN201 was well-tolerated without any serious adverse events or the need for dose adjustments. Based on these outcomes, VYNE has selected higher doses for the ongoing Phase 1b trial. Topline results from this next phase are anticipated in mid-2023.
Read more →VYNE▼ -10.6%on this news· ran to -22% by day 3shared move
VYNE Therapeutics Announces Reverse Stock Split
VYNE Therapeutics announced a 1-for-18 reverse stock split approved by shareholders to comply with Nasdaq's listing requirements. The split will take effect after market close on February 10, 2023. With this action, VYNE aims to enhance its stock's price and improve its compliance with Nasdaq's minimum bid price rules. Following the split, approximately 3.25 million shares will remain outstanding, with adjustments for any fractional shares.
Read more →VYNE▼ -15%on this news· ran to +25% by day 3
VYNE Therapeutics Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201
VYNE Therapeutics has announced the dosing of the first patient with vitiligo in their Phase 1a/b clinical trial for VYN201, a BET inhibitor designed for immuno-inflammatory conditions. The trial aims to generate safety data in healthy volunteers and early clinical proof-of-concept in vitiligo patients. Topline data is anticipated in the first half of 2023, positioning VYNE's drug as a potential treatment option for this condition, for which there is currently limited approved therapy.
Read more →VYNE▼ -14.9%on this news
VYNE Therapeutics to Participate in the LifeSci Partners 12th Annual Corporate Access Event
BRIDGEWATER, N.J., Dec. 12, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced
Read more →VYNEVYNE Therapeutics Announces First Patent Granted for Novel BET Inhibitor Platform
BRIDGEWATER, N.J., Dec. 07, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced
Read more →VYNEVYNE Therapeutics to Participate in Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference
BRIDGEWATER, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced
Read more →VYNEVYNE Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference
BRIDGEWATER, N.J., Nov. 18, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced
Read more →VYNEVYNE Therapeutics Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of Vitiligo
BRIDGEWATER, N.J., Nov. 17, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced
Read more →VYNEVYNE Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update IND clearance received for pan-BD BET inhibitor, VYN201; Anticipate first patient to be enrolled in Phase 1a/b trial for Vitilig
VYNE Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update IND clearance received for pan-BD BET inhibitor, VYN201; Anticipate first patient to be enrolled in Phase 1a/b trial for Vitiligo this month Continued progression of discovery and dev
Read more →VYNEVYNE Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
BRIDGEWATER, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced
Read more →VYNEVYNE Therapeutics Reports Second Quarter 2022 Financial Results BRIDGEWATER, N.J.
VYNE Therapeutics Reports Second Quarter 2022 Financial Results BRIDGEWATER, N.J., August 12, 2022 -- VYNE Therapeutics Inc. (Nasdaq VYNE) ("VYNE" or the "Company"), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of
Read more →VYNE▼ -22.9%on this newsshared move
VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis BRIDGEWATER, N.J.
VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis BRIDGEWATER, N.J., August 10, 2022 -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company"), a biopharmaceutical company developing proprieta
Read more →VYNEThe InhiBET TM Platform Bromodomain & End Terminal (BET) Inhibitors in Autoimmune Disease Iain Stuart, Ph.D Chief Scientific Officer B&T Cell - Mediated Autoimmune Disease Drug Development Conference
The InhiBET TM Platform Bromodomain & End Terminal (BET) Inhibitors in Autoimmune Disease Iain Stuart, Ph.D Chief Scientific Officer B&T Cell - Mediated Autoimmune Disease Drug Development Conference, July 27, 2022 1 Forward Looking Statements This presentation includes forward
Read more →VYNEVYNE Therapeutics to Present at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference
BRIDGEWATER, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced
Read more →VYNEVYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis Top-line Efficacy Results Expected in Approximately 6 to 8 Weeks BRIDGEWATER, N.J.
VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis Top-line Efficacy Results Expected in Approximately BRIDGEWATER, N.J., June 17, 2022 -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company"),
Read more →VYNEVYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference
BRIDGEWATER, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced t
Read more →VYNEKOL Event: Update on the BET InhiBET Platform and VYN201
KOL Event: Update on the BET InhiBET Platform and VYN201 May 17, 2022 Forward Looking Statements This presentation includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , including, but not limited to statements regardin
Read more →VYNEVYNE Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update Announced positive Phase 1b data for FMX114 in mild-to-moderate atopic dermatitis Lead BET inhibitor VYN201 demonstrated positiv
VYNE Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update Announced positive Phase 1b data for FMX114 in mild-to-moderate atopic dermatitis Lead BET inhibitor VYN201 demonstrated positive results across multiple preclinical models of inflamm
Read more →VYNEVYNE Hosting Key Opinion Leader Event on Novel InhiBET™ BET Inhibitor Platform
BRIDGEWATER, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced t
Read more →VYNEVYNE Therapeutics to Present at LifeSci Partners’ Immunology & Inflammation Symposium on May 10th
BRIDGEWATER, N.J., May 06, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced t
Read more →VYNE▲ +9.5%on this news
VYNE Therapeutics Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis At week 2, FMX114 demonstrated a statistically significant reduction i
VYNE Therapeutics Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis N.J., April 7, 2022 -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company"), a biopharmaceutical company developing
Read more →VYNE▲ +7%on this news
VYNE Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an In Vivo Model of Rheumatoid Arthritis VYN201 demonstrated statistically significant improvement in treatment respon
Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an In Vivo Model of Rheumatoid Arthritis BRIDGEWATER, N.J., March 30, 2022 -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company"), a biopharmaceutical company focused on develo
Read more →VYNE▲ +6.1%on this news· ran to +29% by day 3
VYNE Therapeutics Reports Year-End 2021 Financial Results and Provides Corporate Update FMX114 demonstrated preliminary clinical safety and pharmacokinetics in Phase 1b study VYN201 shows promising preclinical data in 3
VYNE Therapeutics Reports Year-End 2021 Financial Results and Provides Corporate Update FMX114 demonstrated preliminary clinical safety and pharmacokinetics in Phase 1b study VYN201 shows promising preclinical data in 3 well-established and validated inflammation models BRI
Read more →VYNEVYNE Reports Positive Preclinical Data for Lead BET Inhibitor, VYN201, in Human Skin Model of Vitiligo VYN201 0.1% and 1% resulted in statistically significant improvement in reducing both melanocyte loss and key inflamm
VYNE Reports Positive Preclinical Data for Lead BET Inhibitor, VYN201, in Human Skin Model of Vitiligo N.J., March 7, 2022 -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company"), a biopharmaceutical company focused on developing proprietary, innovative, and differe
Read more →VYNE▼ -5.3%on this newsshared move
VYNE Therapeutics to Present at 42nd Annual Cowen Healthcare Conference
BRIDGEWATER, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced
Read more →VYNEVYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis Systemic bioavailability of JAK inhibitor (tofacitinib) and S1P receptor modulator (fing
Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis Systemic bioavailability of JAK inhibitor (tofacitinib) and S1P receptor modulator (fingolimod) in topical formulation substantially lower compared to oral equivale
Read more →VYNE▼ -21.5%on this news· ran to -34% by day 3shared move
VYNE Therapeutics Divests Topical Minocycline Assets Transaction includes cash payments of $25 million and potential milestones of up to $450 million Sale aligns with VYNE's strategic plan; proceeds will be used to fund
VYNE Therapeutics Divests Topical Minocycline Transaction includes cash payments of $25 million and potential milestones of up to $450 million Sale aligns with VYNE's strategic plan; proceeds will be used to fund development of Company's immuno-inflammatory pipeline N.J., Ja
Read more →VYNEUnaudited Pro Forma Condensed Consolidated Financial Information Overview On
Unaudited Pro Forma Condensed Consolidated Financial On January 12, 2022 (the "Effective Date"), VYNE Therapeutics Inc. (the "Company" or "VYNE") entered into an Asset Purchase Agreement (the "Agreement") with Journey Medical Corporation ("Journey" or "Buyer") pursuant to whic
Read more →VYNE▼ -9.6%on this news
INVESTOR PRESENTATION January 2022 Forward Looking Statements This presentation includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , including, but not limite
INVESTOR PRESENTATION January 2022 Forward Looking Statements This presentation includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , including, but not limited to statements regarding the development of VYNE's product
Read more →VYNE▲ +10.8%on this newsshared move
VYNE Therapeutics to Participate at the LifeSci Partners 11th Annual Corporate Access Event
BRIDGEWATER, N.J., Jan. 03, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that management will participate in one-on-one investor meetings at the LifeSci Partners 11th Annual Corporate Access Event, to be held virtually J
Read more →VYNE▼ -5.1%on this news
VYNE Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
BRIDGEWATER, N.J., Nov. 18, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference. The presentat
Read more →VYNEVYNE Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update Lead BET Inhibitor Candidate, VYN201, Demonstrates Potent Anti-Inflammatory Effect in Preclinical Studies VYN201 Expected to Ent
VYNE Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update Lead BET Inhibitor Candidate, VYN201, Demonstrates Potent Anti-Inflammatory Effect in Preclinical Studies VYN201 Expected to Enter Clinic in 2022 Phase 2a Results for FMX114 in Mild-t
Read more →VYNELead BET Inhibitor, VYN201, Demonstrates Improvement in Reducing Fibrotic Tissue Mass and Overall Skin Repair Outcomes in Preclinical Study Results support continued progression of VYN201 development program for autoimmu
Lead BET Inhibitor, VYN201, Demonstrates Improvement in Reducing Fibrotic Tissue Mass and Overall Skin Repair Outcomes in Preclinical Study Results support continued progression of VYN201 development program for autoimmune skin diseases BRIDGEWATER, N.J., November 4, 2021 --
Read more →VYNEVYNE Therapeutics to Report Third Quarter 2021 Financial Results on November 10, 2021
BRIDGEWATER, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the third quarter ended September 30, 2021, on Wednesday, November 10, 2021, before the market opens.
Read more →VYNE▲ +14.4%on this newsshared move
Lead BET Inhibitor, VYN201, Significantly Reduces Expression of Several Key Pro-Inflammatory Cytokines in Preclinical Studies - VYN201 exhibits anti-inflammatory effect in preclinical data similar to a super-potent gluco
Lead BET Inhibitor, VYN201, Significantly Reduces Expression of Several Key Pro-Inflammatory Cytokines in Preclinical Studies N.J., October 26, 2021 -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today announced preclinical data showing that its pan-bromodo
Read more →VYNEVYNE Therapeutics Announces Formation of Scientific Advisory Board
Renowned Experts to Support VYNE’s Strategy of Developing Novel Treatments for Immunological and Inflammatory diseases SAB to Help Guide Clinical Development of VYNE’s BET Inhibitor Drug Candidates BRIDGEWATER, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nas
Read more →VYNEVYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
Important milestone achieved as part of the Company’s new corporate strategy to develop treatments for immuno-inflammatory diseases Topline results anticipated in early Q1 2022 BRIDGEWATER, N.J., Oct. 19, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or
Read more →VYNE▼ -5.6%on this news
VYNE Therapeutics Announces its China Partner’s Enrollment of First Patient in Phase 3 Study of AMZEEQ in Patients with Moderate to Severe Acne
BRIDGEWATER, N.J., Oct. 05, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the first patient has been enrolled in a Phase 3 study in China evaluating AMZEEQ® (minocycline) topical foam, 4% in moderate to severe acne.
Read more →VYNE▼ -5.7%on this news
VYNE Therapeutics to Present at the Cantor Fitzgerald Investment Conference
BRIDGEWATER, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the Cantor Fitzgerald Virtual Global Healthcare Conference, to take place September
Read more →VYNEVYNE Therapeutics to Present at the H.C. Wainwright Annual Investment Conference
BRIDGEWATER, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference to be held virtually f
Read more →VYNE▼ -31.1%on this news· ran to -43% by day 3
VYNE Therapeutics Reports Second Quarter 2021 Financial Results and Announces New Strategic Direction to Develop Treatments for Immunological and Inflammatory Diseases Company announced license agreement with In4Derm Lim
VYNE Therapeutics Reports Second Quarter 2021 Financial Results and Announces New Strategic Direction to Develop Treatments for Immunological and Inflammatory Diseases Company announced license agreement with In4Derm Limited for BETi platform earlier this morning Company has in
Read more →VYNE▼ -31.1%on this news· ran to -43% by day 3
have been updated from the footnotes and the report of our Independent Registered Public Accounting Firm to the financial statements included in our Annual Report on Form 10-K for the year ended
The COVID-19 pandemic and government measures taken in response to the pandemic have had a negative impact on the Company's operations. Access to healthcare providers has been limited, which has negatively impacted sales and the Company's ability to execute its commercial strat
Read more →VYNE▼ -31.1%on this news· ran to -43% by day 3
VYNE Therapeutics Announces Licensing of BET Inhibitor Platform for Immuno-Inflammatory Conditions with In4Derm Limited
VYNE will have exclusive access to a library of new chemical entities VYNE will prioritize initial development efforts on rare skin diseases and major immunology and inflammatory conditions with high unmet needs VYNE expects to enter VYN201 and VYN202 into the clinic in 2022 F
Read more →VYNEVYNE Therapeutics Announces Approval of AMZEEQ (Minocycline) and ZILXI (Minocycline) in Chinese Economic Pilot Zone
BRIDGEWATER, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that its products AMZEEQ® (minocycline) topical foam, 4%, and ZILXI® (minocycline) topical foam, 1.5%, have been approved for commercial sale in a
Read more →VYNEVYNE Therapeutics to Report Second Quarter 2021 Financial Results on August 12, 2021
BRIDGEWATER, N.J., July 27, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the second quarter ended June 30, 2021, on August 12, 2021, before the market opens. VYNE will host a
Read more →VYNEVYNE Therapeutics Announces Initiation of Investigator Initiated Trial Evaluating AMZEEQ (Minocycline) with Oral Isotretinoin in Patients with Moderate to Severe Acne
BRIDGEWATER, N.J., July 19, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced the initiation of an investigator initiated trial (“IIT” or “study”) evaluating the safety and efficacy of AMZEEQ® (minocycline) topical foam, 4%,
Read more →VYNEVYNE Therapeutics to Participate in the 2nd Annual JAK Inhibitors Drug Development Digital Event
BRIDGEWATER, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that Dr. Iain Stuart, Chief Scientific Officer, will participate in and moderate a scientific panel discussion at the 2nd Annual JAK Inhibitors Dru
Read more →VYNEVYNE Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update Conference call and live webcast today at 8 30 am Eastern Time BRIDGEWATER, N.J.
VYNE Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update Conference call and live webcast today at 8 30 am Eastern Time BRIDGEWATER, N.J., May 6, 2021 -- VYNE Therapeutics Inc. (Nasdaq VYNE) ("VYNE" or the "Company") today announced financial
Read more →VYNEVYNE Therapeutics to Report First Quarter 2021 Financial Results on May 6, 2021
BRIDGEWATER, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the first quarter ended March 31, 2021, on Thursday, May 6, 2021, before the market opens. VYNE will
Read more →VYNEVYNE Therapeutics Reports Year-End 2020 Financial Results and Provides Business Update Conference call and live webcast to discuss financial results and new FMX114 program in atopic dermatitis today, Thursday
VYNE Therapeutics Reports Year-End 2020 Financial Results and Provides Business Update Conference call and live webcast to discuss financial results and new FMX114 program in atopic dermatitis today, Thursday, March 4, 2021, at 8 30 am Eastern Time BRIDGEWATER, N.J., March 4, 2
Read more →VYNEVYNE Therapeutics to Present at Upcoming Virtual Investor Conferences
BRIDGEWATER, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present and participate at the Barclays Global Healthcare Conference and H.C. Wainwright Globa
Read more →VYNEVYNE Therapeutics to Present at the Cowen 41st Annual Health Care Conference
BRIDGEWATER, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present and participate at the Cowen 41st Annual Health Care Conference. Presentation details
Read more →VYNEVYNE Therapeutics Announces Development Program for FMX114 Combination Topical Gel for Mild-to-Moderate Atopic Dermatitis Announces promising preclinical data on FMX114 Phase 2a clinical study in AD expected to begin in
Announces Development Program for FMX114 Combination Topical Gel for Mild-to-Moderate Atopic Dermatitis Announces promising preclinical data on Phase 2a clinical study in AD expected to begin in 3Q 2021 with top-line results by year end Further details on FMX114, including cl
Read more →VYNEVYNE Therapeutics to Report Financial Results for the Year Ended December 31, 2020 on March 4
BRIDGEWATER, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the year ended December 31, 2020, on Thursday, March 4, 2021, before the market opens. VYNE will host
Read more →VYNEVYNE Therapeutics Announces Reverse Stock Split BRIDGEWATER, N.J.
VYNE Therapeutics Announces Reverse Stock N.J., February 11, 2021 -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today announced that its Board of Directors has approved a reverse stock split of the Company's common stock at a ratio of 1-for-4. The reverse
Read more →VYNEVYNE Therapeutics Announces FDA Approval of AMZEEQ (Minocycline) Label Update
BRIDGEWATER, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced approval
Read more →VYNEVYNE Therapeutics Announces Closing of $50 Million Registered Direct Offering of Common Stock and Provides Corporate Update
BRIDGEWATER, N.J., Jan. 29, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it has closed its previously announced registered direct offering of an aggregate of 21,097,046 shares of common stock at a purchase price of
Read more →VYNEVYNE Therapeutics Announces $50 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules
BRIDGEWATER, N.J., Jan. 26, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), today announced that it has entered into definitive agreements with institutional and accredited investors for the sale of an aggregate of 21,097,046 shares of i
Read more →VYNEVYNE Therapeutics Announces Contract Execution for AMZEEQ (minocycline) and ZILXI (minocycline) with Major Pharmacy Benefit Management (PBM) Company
BRIDGEWATER, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced the execution of a contract with a major PBM for its novel AMZEEQ® (minocycline) topical foam, 4% and ZILXI® (minocycline) topical foam, 1.5%. AMZE
Read more →VYNEInvestor Presentation January 2021 Forward Looking Statements This presentation includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , including, but not limite
Investor Presentation January 2021 Forward Looking Statements This presentation includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , including, but not limited to statements regarding the development and commercializa
Read more →VYNEVYNE Therapeutics to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event this Week
BRIDGEWATER, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will participate in two panel presentations at the LifeSci Partners 10th Annual Healthcare Corporate
Read more →VYNEVYNE Therapeutics Reports Successful End-of-Phase 2 Meeting with the FDA for FCD105 in Acne
BRIDGEWATER, N.J., Dec. 17, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) , a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced the suc
Read more →VYNEVYNE Therapeutics Added to Nasdaq Biotechnology Index
BRIDGEWATER, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that it has been selected
Read more →VYNEVYNE Therapeutics Announces New U.S. Patent Expiring in 2037 for AMZEEQ (minocycline) topical foam, 4%
BRIDGEWATER, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced listing
Read more →VYNEVYNE Therapeutics Announces Publication of Long-term Safety & Efficacy Data for ZILXI™ (minocycline) topical foam, 1.5% in the Journal of Clinical and Aesthetic Dermatology
ZILXI is the First FDA Approved Minocycline Product for the Treatment of Inflammatory Lesions of Rosacea in Adults ZILXI demonstrated a favorable safety and tolerability profile for up to 52 weeks of treatment Efficacy of ZILXI continued to develop for an additional 40 weeks of
Read more →VYNEVYNE Therapeutics to Present at the 32nd Annual Piper Sandler Healthcare Conference
BRIDGEWATER, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will participate in a fireside chat at the virtual Piper Sandler Healthcare Conference being held De
Read more →VYNEVYNE Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update Conference Call Today at 8 30am Eastern Time BRIDGEWATER, N.J., November 5 th , 2020 -- VYNE Therapeutics Inc. (Nasdaq VYNE) ("V
VYNE Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update Conference Call Today at 8 30am Eastern Time BRIDGEWATER, N.J., November 5th, 2020 -- VYNE Therapeutics Inc. (Nasdaq VYNE) ("VYNE" or the "Company") today announced financial results for
Read more →VYNEVYNE Therapeutics to Report Third Quarter 2020 Financial Results on November 5th
BRIDGEWATER, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the third quarter ended September 30, 2020, on Thursday, November 5, 2020, before the market opens. V
Read more →VYNEVYNE Therapeutics Announces Covered Status for ZILXI™ (minocycline) with Express Scripts
BRIDGEWATER, N.J., Oct. 07, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced a coverage update for its novel ZILXI™ (minocycline) topical foam, 1.5%. ZILXI is the first minocycline product of any form to be FDA approved for
Read more →VYNEVYNE Therapeutics Announces Covered Status for ZILXI (minocycline) with Express Scripts Coverage Effective
Announces Covered Status for ZILXI (minocycline) with Express Scripts Effective October 2, 2020 on Express Scripts National Preferred, Flex, and Basic Formularies BRIDGEWATER, N.J., Oct. 7, 2020 - VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today announced
Read more →VYNEVYNE Therapeutics Announces ZILXI (minocycline) topical foam, 1.5% Available in Pharmacies Nationwide on October 1st ZILXI is the First FDA Approved Minocycline Product for the Treatment of Inflammatory Lesions of Rosace
VYNE Therapeutics Announces ZILXI (minocycline) topical foam, 1.5% Available in Pharmacies Nationwide on October 1st ZILXI is the First FDA Approved Minocycline Product for the Treatment of Inflammatory Lesions of Rosacea in Adults ZILXI Offers Efficacy with Low Systemic B
Read more →VYNEVYNE Therapeutics to Host Physician Symposium on AMZEEQ and ZILXI™
BRIDGEWATER, N.J., Sept. 23, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the Company will host a physician symposium on AMZEEQ® and ZILXI™ on Thursday, October 1, 2020 from 12pm – 3pm ET. The webinar will feature
Read more →VYNEVYNE Therapeutics Announces the Appointment of Patrick G. LePore to its Board of Directors Bridgewater, NJ
Announces the Appointment of Patrick G. LePore to its Board of Directors Bridgewater, NJ - September 14, 2020 - VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today announced that the Board of Directors of the Company appointed Mr. Patrick G. LePore to serve a
Read more →VYNEVYNE Therapeutics (formerly Menlo Therapeutics) to Present at the Cantor Fitzgerald and H.C. Wainwright Investment Conferences in September
BRIDGEWATER, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the upcoming H.C. Wainwright 22nd Annual Global Investment Conference and the Canto
Read more →VYNEMenlo Therapeutics Announces Completion of Corporate Name Change to VYNE Therapeutics Will commence trading under new Nasdaq Ticker "VYNE"
Therapeutics Announces Completion of Corporate Name Change to VYNE Therapeutics Will commence trading under new Nasdaq Ticker "VYNE", September 8, 2020 Company to ring Nasdaq Closing Bell at 4pm Bridgewater, NJ - September 8, 2020 - VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VY
Read more →VYNEMenlo Therapeutics Announces Corporate Name Change to VYNE Therapeutics Company will commence trading under new ticker "VYNE" on
Therapeutics Announces Corporate Name Change to VYNE Therapeutics commence trading under new ticker "VYNE" on September 8, 2020 ring Nasdaq Closing Bell on September 8 Bridgewater, NJ - September 2, 2020 - Menlo Therapeutics Inc. (Nasdaq: MNLO) ("Menlo" or the "Company") anno
Read more →VYNEMenlo Reports Second Quarter 2020 Financial Results and Provides Business Update Conference Call Today at 8 30am Eastern Time BRIDGEWATER, N.J.
Menlo Reports Second Quarter 2020 Financial Results and Provides Business Update Conference Call Today at 8 30am Eastern Time BRIDGEWATER, N.J., August 6, 2020 -- Menlo Therapeutics Inc. (Nasdaq MNLO) ("Menlo" or the "Company"), a specialty pharmaceutical company focused on dev
Read more →VYNEMenlo Therapeutics Announces Positive Results from Phase 2 Trial of FCD105 for the Treatment of Moderate-to-Severe Acne Vulgaris The Company plans to present trial data along with a proposed Phase 3 development program i
Menlo Therapeutics Announces Positive 2 Trial of FCD105 for the Treatment of Moderate-to-Severe The Company plans to present trial data along with a proposed Phase 3 development program in an End of Phase 2 meeting with the FDA before the BRIDGEWATER, New Jersey, June 02, 20
Read more →VYNEInvestor Presentation June 2020 Forward Looking Statements This presentation includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , including, but not limited t
Investor Presentation June 2020 Forward Looking Statements This presentation includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , including, but not limited to statements regarding the development and commercializatio
Read more →VYNETherapeutics Receives FDA Approval of ZILXI (minocycline) topical foam, 1.5%, the First Topical Minocycline Treatment for
Therapeutics Receives FDA Approval of ZILXI (minocycline) topical foam, 1.5%, the First Topical Minocycline Treatment for ZILXI Now Approved for Inflammatory Lesions of Rosacea in Adults BRIDGEWATER, N.J., May 29, 2020 - Menlo Therapeutics Inc. (Nasdaq: MNLO) ("Menlo" or the
Read more →VYNEMenlo Reports First Quarter 2020 Financial Results and Provides Business Update Conference Call Today at 8:30am Eastern Time BRIDGEWATER, N.J.
Reports First Quarter 2020 Financial Results and Provides Business Update Call Today at 8:30am Eastern Time BRIDGEWATER, N.J., May 11, 2020 -- Menlo Therapeutics Inc. (Nasdaq: MNLO) ("Menlo" or the "Company"), a specialty pharmaceutical company focused on developing and comme
Read more →VYNEMenlo Therapeutics Announces Results from Two Phase 3 Clinical Trials of Serlopitant for the Treatment of Pruritus Associated with Prurigo Nodularis Conference call today at 8.30am EDT BRIDGEWATER, New Jersey
Announces Results from Two Phase 3 Clinical Trials of Serlopitant for the Treatment of Pruritus Associated with Prurigo Nodularis BRIDGEWATER, New Jersey, April 06, 2020 -- Menlo Therapeutics Inc. (Nasdaq: MNLO) ("Menlo" or the "Company"), a biopharmaceutical company focused o
Read more →VYNEMenlo Therapeutics Appoints Andrew Saik as Chief Financial Officer BRIDGEWATER, N.J.
Menlo Therapeutics Appoints Andrew Saik as Chief Financial Officer BRIDGEWATER, N.J., March 24, 2020 -- Menlo Therapeutics Inc. (Nasdaq: MNLO) ("Menlo" or the "Company"), a biopharmaceutical company focused on developing and commercializing proprietary therapies to address un
Read more →VYNEMenlo Reports Financial Results for Subsidiary Foamix Pharmaceuticals for Year Ended
Financial Results for Subsidiary Foamix Pharmaceuticals for Year Ended December 31, 2019 Became a Wholly Owned Subsidiary of Menlo Therapeutics Upon Closing of Merger on March 9, 2020 Conference Call and Webcast Scheduled for Thursday, March 12th at 8:30am Eastern Time BRIDGEW
Read more →VYNEMenlo Therapeutics and Foamix Pharmaceuticals Complete Merger, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications BRIDGEWATER, N.J.
Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic BRIDGEWATER, N.J., March 9, 2020 - Menlo Therapeutics Inc. (Nasdaq: MNLO) ("Menlo" or the "Company") ann
Read more →VYNEMenlo Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
Menlo Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results REDWOOD CITY, Calif., March 3, 2020 -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), to
Read more →VYNEFoamix and Menlo Announce Shareholder Approval of Proposed Merger Transaction on Track to Close in early March 2020 REHOVOT, Israel, BRIDGEWATER, N.J. and
Foamix and Menlo Announce Shareholder Approval of Proposed Merger Transaction on Track to Close in early March 2020 REHOVOT, Israel, BRIDGEWATER, N.J. and REDWOOD CITY, C.A., February 6, 2020 Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX ) and Menlo Therapeutics Inc. (Nasdaq: MNLO
Read more →VYNEForward-Looking Statements This presentation contains forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties that could cause our actual results to
Investor Presentation | November 11, 2019 A Compelling Dermatology Combination Exhibit 99.1 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties tha
Read more →VYNEMenlo Therapeutics Reports Third Quarter 2019 Financial Results and Provides Program Updates - Pivotal Data from two Phase 3 Trials in Prurigo Nodularis Expected March/April 2020 and Phase 2 Trial Results in Chronic Prur
Menlo Therapeutics Reports Third Quarter 2019 Financial Results and Provides Program Updates - Pivotal Data from two Phase 3 Trials in Prurigo Nodularis Expected March/April 2020 and Phase 2 Trial Results in Chronic Pruritus of Unknown Origin Expected January/February 2020 - R
Read more →VYNEMenlo Therapeutics Reports Second Quarter 2019 Financial Results and Provides Program Updates Including Accelerated Timeline for Upcoming Clinical Data ~Results from Serlopitant Phase 2 Clinical Trial for the Treatment o
Menlo Therapeutics Reports Second Quarter 2019 Financial Results and Provides Program Updates Including Accelerated Timeline for Upcoming Clinical Data ~Results from Serlopitant Phase 2 Clinical Trial for the Treatment of Chronic Pruritus of Unknown Origin Anticipated in Q1 2020
Read more →VYNEMenlo Therapeutics Reports First Quarter 2019 Financial Results
Menlo Therapeutics Reports First Quarter 2019 Financial Results REDWOOD CITY, Calif., May 2, 2019 -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced fin
Read more →VYNEMenlo Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
Menlo Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results REDWOOD CITY, Calif., February 27, 2019 -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch)
Read more →VYNEMenlo Therapeutics' Successful Phase 2 Clinical Trial of Serlopitant Demonstrates Reduction of Pruritus Associated with Psoriasis Company to Conduct Conference Call and Webcast Today at 8:00am ET / 5:00am
Menlo Therapeutics' Successful Phase 2 Clinical Trial of Serlopitant Demonstrates Reduction of Pruritus Associated with Psoriasis Company to Conduct Conference Call and Webcast Today at 8:00am ET / 5:00am PT REDWOOD CITY, Calif., December 10, 2018 -- Menlo Therapeutics Inc. (N
Read more →VYNEMenlo Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update ~ Phase 2 Data in Psoriasis Expected December 2018 ~ ~ New Phase 2 Clinical Trial in Chronic Pruritus of Unknown Origin Expecte
Menlo Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update ~ Phase 2 Data in Psoriasis Expected December 2018 ~ ~ New Phase 2 Clinical Trial in Chronic Pruritus of Unknown Origin Expected to Start in Q4 2018 ~ ~ Prurigo Nodularis Phase 3 Clini
Read more →VYNEMenlo Therapeutics Announces Results from a Phase 2 Clinical Trial of Serlopitant for the Treatment of Refractory Chronic Cough Serlopitant fails to demonstrate efficacy relative to placebo on primary and secondary endpo
Menlo Therapeutics Announces Results from a Phase 2 Clinical Trial of Serlopitant for the Treatment of Refractory Chronic Cough Serlopitant fails to demonstrate efficacy relative to placebo on primary and secondary endpoints REDWOOD CITY, Calif., October 8, 2018 -- Menlo Therap
Read more →VYNEMenlo Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update ~ Phase 2 Data in Refractory Chronic Cough Expected in October 2018 ~ ~ Phase 2 Data in Psoriasis Expected December 2018 or Ja
Menlo Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update ~ Phase 2 Data in Refractory Chronic Cough Expected in October 2018 ~ ~ Phase 2 Data in Psoriasis Expected December 2018 or January 2019 ~ ~ New Phase 2 Study in Chronic Pruritus of U
Read more →VYNEMenlo Therapeutics Reports First Quarter 2018 Financial Results
Menlo Therapeutics Reports First Quarter 2018 Financial Results REDWOOD CITY, Calif., May 9, 2018 -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus associated with various und
Read more →VYNEMenlo Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
Menlo Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results REDWOOD CITY, Calif., March 28, 2018 -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant, for the treatment of pruritus associat
Read more →VYNEfor Menlo Therapeutics: media@menlotx.com Investor Contact: patti.bank@westwicke.com
Menlo Therapeutics Inc. Announces Pricing of Initial Public Offering of Common Stock REDWOOD CITY, Calif., January 24, 2018 - Menlo Therapeutics Inc. (NASDAQ:MNLO) today announced the pricing of the Company's initial public offering of 7,000,000 shares of common stock at a publi
Read more →Competitive Position
How VYNE ranks across every disease it competes inCompetitive Position is a premium feature
See how VYNE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial